Makes hyaluronic acid injections for knee osteoarthritis.
Jun 2026Revenue $582M/yrExpenses $524M/yr
No trend
Figures by year
Is Bioventus profitable?
Yes. In the 12 months to Jun 2026, revenue was $582M and expenses $524M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $568M | $514M | $54.0M |
| Dec 2024 | $573M | $588M | −$15.2M |
| Dec 2023 | $512M | $594M | −$81.7M |
| Dec 2022 | $512M | $679M | −$167M |
| Dec 2021 | $431M | $419M | $12.1M |
| Dec 2020 | $321M | $300M | $21.2M |
| Dec 2019 | $340M | $309M | $31.2M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.